Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17477593 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL3408206 | 0.78 | CES2 (0.37) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL18587153 | 0.78 | IDO1 (0.37) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL142651 | 0.75 | KLF10 (0.40) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL30377054 | 0.75 | KLF10 (0.40) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL19165621 | 0.75 | FFAR4 (0.35) | CYP3A4CYP2D6MAPTMEN1LMNA | |
| SCHEMBL475304 | 0.73 | IDO1 (0.41) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL29382636 | 0.73 | IDO1 (0.41) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL3410622 | 0.73 | IDO1 (0.42) | CYP3A4CYP2D6IDO1CES2TAS2R14 | |
| SCHEMBL25085860 | 0.72 | IDO1 (0.43) | CYP3A4CYP2D6IDO1TAS2R14PIEZO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174537-B1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3174537-B1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME (US) | 2021-06-23 | — | — | EP | disclosed |
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3174537-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | Merck Sharp & Dohme Corp. (US) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016018729-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016018729-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011572-B2 | Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein | CETP, MTTP, LCAT | CYP3A4 414/4885CYP2D6 1563/4885IDO1 3994/4885 |
| US-20170210715-A1 | MONOCYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN | CETP, MTTP, LCAT | CYP3A4 414/4885CYP2D6 1563/4885IDO1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.